Retatrutide outcomes program advances through Phase 3
What large ongoing trials are designed to answer—and why retatrutide remains investigational.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What happened?
The registered Phase 3 retatrutide program includes large studies of obesity and related outcomes. The TRIUMPH-Outcomes record describes a cardiovascular and kidney outcomes trial with an estimated enrollment of 10,000 participants.
Other registered studies compare retatrutide with placebo or tirzepatide in defined populations. Trial records can change as studies progress, so status should be verified directly.
Why it matters
- Large, longer trials can answer questions that smaller early studies cannot, including uncommon harms and whether changes in weight or biomarkers lead to meaningful health outcomes.
- The existence of Phase 3 trials is evidence that a serious research program is underway; it is not evidence of FDA approval.
What changed for patients or consumers?
- Nothing changed for routine patient care: retatrutide remains an investigational drug without an FDA-approved product.
- The program's scale makes it possible to learn more over time, but readers should avoid treating estimated dates or trial registration as a result.
What remains uncertain?
- Whether pivotal trials will meet their primary endpoints
- The full safety profile in larger and longer studies
- What indication, label, or formulation regulators might consider if a future application is submitted
- Final completion dates, which are estimates and may change
Related fact sheets
Source links
- 1ClinicalTrials.gov: TRIUMPH-Outcomes
Registered cardiovascular and kidney outcomes study.
- 2ClinicalTrials.gov: TRIUMPH-5
Registered Phase 3 comparison with tirzepatide in adults with obesity.
- 3PubMed: retatrutide literature
Peer-reviewed research indexed by the National Library of Medicine.